Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study

作者：Shun Lü, Jianying Zhou, Hong Jian, Lin Wu, Ying Cheng, Yun Fan, Jian Fang, Gongyan Chen, Zhihong Zhang, Dongqing Lv, Liyan Jiang, Rong Wu, Xiangming Jin, Xiaodong Zhang, Junhong Zhang, Conghua Xie, Gengyun Sun, Dongning Huang, Jiuwei Cui, Renhua Guo, Zhigang Han, Zhendong Chen, Jin Liang, Wu Zhuang, Xingsheng Hu, Aimin Zang, Yi Zhang, Shundong Cang, Yuanbo Lan, Xi Chen, Laiyu Liu, Xingya Li, Jun Chen, Rui Ma, Yanzhen Guo, Ping Sun, Panwen Tian, Yueyin Pan, Zhe Liu, Peiguo Cao, Lieming Ding, Yang Wang, Xiaobin Yuan, Pengxiang Wu · 发表于：The Lancet Respiratory Medicine · 年份：2023 · DOI：10.1016/s2213-2600(23)00183-2 · 被引用次数：75 · 研究领域：Lung Cancer Treatments and Mutations、Lung Cancer Research Studies、Advanced Breast Cancer Therapies